Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages 389-404

  Cortes, Jorge E ^a   Jones, Dan ^a   O'Brien, Susan ^a   Jabbour, Elias ^a   Ravandi, Farhad ^a   Koller, Charles ^a   Borthakur, Gautam ^a   Walker, Brenda ^a   Zhao, Weiqiang ^a   Shan, Jianqin ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACNE; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; EVENT FREE SURVIVAL; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MEMORY DISORDER; MYALGIA; NEUTROPENIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; RECTUM HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; MIDDLE AGED; MYELOID LEUKEMIA; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PYRIMIDINES; THIAZOLES; YOUNG ADULT;

EID: 75749129911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4920     Document Type: Article

References (25)

1. O'Brien SG, Guilhot F, Goldman J, et al: International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112:186, 2008 (abstr)
2. Kantarjian HM, Talpaz M, O'Brien S, et al: Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108:1835-1840, 2006
3. Roy L, Guilhot J, Krahnke T, et al: Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood 108: 1478-1484, 2006
4. Baccarani M, Martinelli G, Rosti G, et al: Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104:4245-4251, 2004
5. Kantarjian H, Talpaz M, O'Brien S, et al: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004
6. Cortes J, Kantarjian H: Beyond dose escalation: Clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw 6:S22-S30, 2008 (suppl 2)
7. Redaelli S, Piazza R, Rostagno R, et al: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469-471, 2009
8. Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007
9. Hochhaus A, Baccarani M, Deininger M, et al: Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200-1206, 2008
10. Cortes J, Kantarjian H, Kim D-W, et al: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood 112:1098, 2008 (abstr)
11. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004
12. Lombardo LJ, Lee FY, Chen P, et al: Discovery ofN-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658-6661, 2004
13. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006
14. Cortes J, Talpaz M, O'Brien S, et al: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11:3425-3432, 2005
15. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
16. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363, 2008
17. Bradeen HA, Eide CA, O'Hare T, et al: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 108:2332-2338, 2006
18. Cortes J, Baccarani M, Guilhot F, et al: A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CMLCP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. Blood 112:335, 2008 (abstr)
19. Guilhot F, Larson R, O'Brien S: Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. Blood 110:27, 2007 (abstr)
20. Quintas-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321, 2009
21. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
22. Cortes JE, Kantarjian HM, Goldberg SL, et al: High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754-4759, 2009
23. Shah NP, Kantarjian HM, Kim DW, et al: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26: 3204-3212, 2008
24. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
25. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006